drugset / Trial / NCT00134511

Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder

NCT00134511

Phase 3 Completed 30 enrolled Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To evaluate the efficacy and safety of the lipid drug Torcetrapib/atorvastatin in patients with genetically known disorder of extremely high cholesterol

Timeline

Start
2005-03
Primary completion
Completion
2005-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule Oral
Subject torcetrapib Small molecule Oral